Members log in

Remember me

Do not refresh my screen on timeout

close

News

ABN May newsletter has been published.

Read More

Events

ABN Autumn Meeting 12 October 2017. For this and other meeting details click read more.

Read More

Trials and Surveys

Trials 

 

SANADII

SANADII needs you! With the end of recruitment in May 2017 please make every effort to recruit. Should you have any questions about recruitment (or trial in general) please contact Silviya Balabanova (trial coordinator) tel 0151 529 5464, or Tony Marson (CI). SANADII is a National Institute for Health Research's Health Technology Assessment programme (NIHR HTA) funded trial and it assesses the clinical and cost effectiveness of levetiracetam and zonisamide compared to standard treatments - lamotrigine and valproate over 5.5 years. For more information visit  www.sanad2.org.uk.

 

 

ECST-2

The Second European Carotid Surgery Trial (ECST-2) is a multicentre randomised controlled trial (RCT), funded by the NIHR Research for Patient Benefit Scheme and by the Stroke Association, UK.  The trial is designed to investigate the hypothesis that in patients with atherosclerotic carotid artery stenos is at low and intermediate risk for stroke, optimised medical treatment (OMT) will avoid the need for carotid revascularisation.  Asymptomatic or symptomatic patients with >50% carotid artery stenosis and a low to intermediate risk of recurrent stroke, will be randomly allocated to be treated by carotid revascularisation with OMT  (“immediate revascularisation”) or OMT alone (“delay revascularisation until more clearly indicated”).  Substudies of the trial include carotid plaque imaging with MRI and US, histological analysis of the plaque and genetics.  The ECST-2 Trial Group, led by Professor Martin Brown (Chief Investigator) is based at the UCL Institute of Neurology, London UK.  For further information on the trial please contact Dr Roland Featherstone, Trial Manager.  Alternatively you can visit the trial website.

 

 

Leber’s Hereditary Optic Neuropathy Gene Therapy Trial

We have started recruitment into these two LHON gene therapy trials for patients with the 11778 mtDNA mutation.    Rescue:  Vision loss for 6 months or less https://clinicaltrials.gov/ct2/show/NCT02652767?term=GenSight+Biologics&rank=2    Reverse:  Vision loss for 6-12 months https://clinicaltrials.gov/ct2/show/NCT02652780?term=GenSight+Biologics&rank=1    The procedure consists of an intravitreal injection of the viral vector (GS010) in one eye under topical anaesthesia.    Since this information was last circulated on the UK EGG mailing list, we have now received ethical approval to reduce the age threshold from 18 to 15 years old.    All travel expenses for the patient and an accompanying person (if required) will be covered.  If you have any eligible patients or any queries, please get in touch with me (Patrick.Yu-Wai-Man@ncl.ac.uk).

 


 

Surveys

 

Parkinson’s UK Survey  

Do you speak to people affected by Parkinson’s?

We want to provide support and resources to help health care professionals confidently speak to people affected by Parkinson’s about taking part in research and signpost them to relevant opportunities – and to do this we need your input and experiences!

Please help by taking 5 minutes to fill in our short online survey: http://surveys.parkinsons.org.uk/s/helping-people-to-takepart/

 

 

Cluster Headache Imaging Study in King's College London

There is limited understanding of what causes cluster headache, hence the Headache Group at King's College London is committed to discovering more. We are interested in how many cluster headache patients you see per year.

How many have chronic cluster headache?

How many have episodic cluster headache?

Please reply to Dr Diana Wei via email clusterheadache-research@kcl.ac.uk

 

News

ABN May newsletter has been published.

Read More

Events

ABN Autumn Meeting 12 October 2017. For this and other meeting details click read more.

Read More